Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Adalimumab F(ab')2.
Recognizes Adalimumab specifically, no cross reactivity with other humanized antibodies.
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A specially optimized long-spacer biotin reagent (13.5 angstroms) is used in this product to minimize potential steric hindrance.
The biotin to protein ratio is 1-3 as determined by the HABA assay.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 years under sterile conditions after reconstitution.
Biotinylated Anti-Adalimumab Antibodies (recommended for PK/PD) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Detection of adalimumab by bridging ELISA in serum. Immobilized Anti-Adalimumab Antibodies (Cat. No. ADB-Y23) at 2 μg/mL, add increasing concentrations of adalimumab (10% human serum) and then add Biotinylated Anti-Adalimumab Antibodies (Cat. No. ADB-BY17) at 2 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 4.8 ng/mL.
Immobilized adalimumab at 1 μg/mL (100 μL/well) can bind Biotinylated Anti-Adalimumab Antibodies (Cat. No. ADB-BY17) with a linear range of 0.78-25 ng/mL.
ELISA analysis shows that the binding of adalimumab to Human TNF-alpha, Tag Free, low endotoxin (Cat. No. TNA-H4211) was inhibited by increasing concentration of Biotinylated Anti-Adalimumab Antibodies (Cat. No. ADB-BY17). The concentration of adalimumab used is 6 ng/mL. The IC50 is 4.399 μg/mL.
Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.